2-Quinoxalinamine, N,N-diethyl-7-[5-fluoro-2-[[5-(1-piperazinyl)-2-pyridinyl]amino]-4-pyrimidinyl]-

Request For Quotation
2-Quinoxalinamine, N,N-diethyl-7-[5-fluoro-2-[[5-(1-piperazinyl)-2-pyridinyl]amino]-4-pyrimidinyl]- Suppliers list
Company Name: TargetMol Chemicals Inc.  
Tel: 15002134094
Email: marketing@targetmol.cn
Company Name: TargetMol Chemicals Inc.  
Tel: 13564774135
Email: marketing@targetmol.com

2-Quinoxalinamine, N,N-diethyl-7-[5-fluoro-2-[[5-(1-piperazinyl)-2-pyridinyl]amino]-4-pyrimidinyl]- manufacturers

  • CDK6/PIM1-IN-1
  • CDK6/PIM1-IN-1 pictures
  • $1980.00
  • 2026-07-27
  • CAS:2677026-14-9
  • Purity:
  • Supply Ability: 10g
2-Quinoxalinamine, N,N-diethyl-7-[5-fluoro-2-[[5-(1-piperazinyl)-2-pyridinyl]amino]-4-pyrimidinyl]- Basic information
Product Name:2-Quinoxalinamine, N,N-diethyl-7-[5-fluoro-2-[[5-(1-piperazinyl)-2-pyridinyl]amino]-4-pyrimidinyl]-
Synonyms:2-Quinoxalinamine, N,N-diethyl-7-[5-fluoro-2-[[5-(1-piperazinyl)-2-pyridinyl]amino]-4-pyrimidinyl]-;CDK6/PIM1-IN-1
CAS:2677026-14-9
MF:C25H28FN9
MW:473.55
EINECS:
Product Categories:
Mol File:2677026-14-9.mol
2-Quinoxalinamine, N,N-diethyl-7-[5-fluoro-2-[[5-(1-piperazinyl)-2-pyridinyl]amino]-4-pyrimidinyl]- Structure
2-Quinoxalinamine, N,N-diethyl-7-[5-fluoro-2-[[5-(1-piperazinyl)-2-pyridinyl]amino]-4-pyrimidinyl]- Chemical Properties
Boiling point 716.9±70.0 °C(Predicted)
density 1.299±0.06 g/cm3(Predicted)
pka8.63±0.10(Predicted)
Safety Information
MSDS Information
2-Quinoxalinamine, N,N-diethyl-7-[5-fluoro-2-[[5-(1-piperazinyl)-2-pyridinyl]amino]-4-pyrimidinyl]- Usage And Synthesis
UsesCDK6/PIM1-IN-1 is a potent and balanced dual CDK6/PIM1 inhibitor with IC50values of 39 and 88 nM, respectively.CDK6/PIM1-IN-1 inhibits CDK4 (IC50=3.6 nM). CDK6/PIM1-IN-1 significantly inhibits acute myeloid leukemia (AML) cell proliferation, arrest cell cycle at the G1 phase, and promote cell apoptosis. CDK6/PIM1-IN-1 exhibits potent anti-AML activity[1].
in vivo

CDK6/PIM1-IN-1 (compound 51; orally; 60, 90 mg/kg/day; 17 days) displays more potent antitumor activityin BALB/c mice with K562 cell lines[1].
CDK6/PIM1-IN-1 (iv; 5 mg/kg) has the t1/2, MRT0-∞, and AUC0-∞values of 9.78 h, 14.61 h, and 1153.74 h·ng/mL, respectively in Sprague–Dawley (SD) rats[1].
CDK6/PIM1-IN-1 (po; 5 mg/kg) has thet1/2, Tmax, Cmax, and AUC0-∞ of 15.81 h, 11 h, 152.31 ng/mL, and 5152.92 h·ng/mL, respectively in SD rats[1].

IC 50CDK6/cyclinD1: 39 nM (IC50); CDK1/cyclinB: >10 μM (IC50); CDK2/cyclinA: 2.274 μM (IC50); CDK3/Cyclin E: >10 μM (IC50); Cdk4/cyclin D1: 3.6 nM (IC50); Cdk5/p25: >10 μM (IC50); CDK7/Cyclin H/MNAT1: 393 nM (IC50); CDK9/cyclinT1: 440 nM (IC50); CDK12/Cyclin K: >10 μM (IC50); CDK13/Cyclin K: >10 μM (IC50); PIM1: 88 nM (IC50); PIM2: >10 μM (IC50); PIM3: 92 nM (IC50)
References[1] Kai Yuan, et al. Discovery of Dual CDK6/PIM1 Inhibitors with a Novel Structure, High Potency, and Favorable Druggability for the Treatment of Acute Myeloid Leukemia. J Med Chem. 2022 Jan 13;65(1):857-875. DOI:10.1021/acs.jmedchem.1c02019
2-Quinoxalinamine, N,N-diethyl-7-[5-fluoro-2-[[5-(1-piperazinyl)-2-pyridinyl]amino]-4-pyrimidinyl]- Preparation Products And Raw materials
Tag:2-Quinoxalinamine, N,N-diethyl-7-[5-fluoro-2-[[5-(1-piperazinyl)-2-pyridinyl]amino]-4-pyrimidinyl]-(2677026-14-9) Related Product Information
2-Quinoxalinamine, N,N-diethyl-7-[5-fluoro-2-[[5-(1-piperazinyl)-2-pyridinyl]amino]-4-pyrimidinyl]- Doxorubicin hydrochloride CDK12-CCNK HETERODIMER Protein, HUMAN (SF9) CDK3-CCNE1 HETERODIMER Protein, HUMAN (SF9) Ruxolitinib 2-Deoxy-D-glucose